In The News
AINovo™ Biotech at BIO 2020
AINovo™ Biotech was featured on the Nothing Stops Innovation Panel with Johnson & Johnson Innovation at BIO 2020. Our CEO, Anvita Gupta, appeared on the panel with Seema Kumar, Vice President of Innovation, Global Health and Policy Communication at Johnson & Johnson. "Each year, the Biotechnology Institute honors a past BioGENEius who best exemplifies the goals of its mission. This year, we honor Anvita Gupta, former BioGENEius winner and currently CEO of AINovo™ Biotech."
Protein-based therapeutics are at the forefront of biomedical research, and have been used to treat a variety of conditions with unmet medical needs. Biologics such as therapeutic antibodies have transformed the field of oncology and led to transformative cancer immunotherapy treatments.
At the same time, the increase in genomic sequencing, proteomic data, real world evidence, and electronic health records have led to a wealth of available information which can be leveraged to extract relevant pharmaceutical insights. Cutting-edge artificial intelligence algorithms in computer vision, natural language processing, and generative machine learning have matured and can be brought to bear on these curated datasets to enable data-driven decision making in pharmaceutical R&D problems.
AINovo™ Biotech Inc. is leveraging this unique interdisciplinary opportunity afforded by massively growing biomedical datasets, modern machine learning algorithms, and growing unmet medical needs in order to accomplish our mission of enabling data-driven discovery of novel biologic therapeutics and diagnostics for patients.
New Generation Biologics. Designed and Optimized with AI.
Data-driven biologics design and optimization. Meet our biological data engine (AICurius™), protein design engine (AIGenus™), and biologics optimization engine (AIOptimus™).
Our Focus Areas
We develop transformative therapeutics across multiple disease areas through joint-development partnerships as well as internal development programs.
Antibiotic resistance is one of the biggest public health challenges of our time. We discover novel therapeutics and diagnostics to alleviate the high burden of antibiotic-resistant infections and battle emerging pathogenic threats.
We design and optimize highly specific antibody-based drugs for cancer immunotherapy applications, as well as novel classes of biologics to battle challenging and particularly aggressive forms of cancer.
Using our proprietary data engine, AICurius™ and deep learning algorithms, AINovo™ Biotech Inc. is optimizing and engineering novel biologically-based rapid, point-of-care diagnostics, including a special ongoing project for COVID-19.